A phase IIb, randomized, parallel group, double-blind, double-dummy, multi-center, multi-national, multi-dose study of DU-176b compared to dalteparin in patients undergoing elective unilateral total hip replacement

Trial Profile

A phase IIb, randomized, parallel group, double-blind, double-dummy, multi-center, multi-national, multi-dose study of DU-176b compared to dalteparin in patients undergoing elective unilateral total hip replacement

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Edoxaban (Primary) ; Dalteparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Therapeutic Use
  • Acronyms STARTS-II
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 29 Jun 2010 Results published in Thrombosis and Haemostasis.
    • 02 Sep 2008 Results presented at the European Society of Cardiology Congress 2008.
    • 30 Aug 2008 Primary endpoint 'Venous thromboembolism event rate' has been met, according to results reported at the Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top